Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosin...
July 08 2019 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of
its latest clinical study were published Friday in the journal
Scientific Reports. The largest trial of nicotinamide riboside (NR)
published to date, the new study further validates the safety and
efficacy of ChromaDex’s proprietary form of NR, Niagen®.
“The results of this large human trial directly support the
efficacy and safety of our NAD-boosting consumer product Tru
Niagen,” says ChromaDex CEO Rob Fried. “The study also provides key
data points for regulatory submissions as we continue our global
expansion.”
This is the first clinical trial to measure both the kinetics
and dose-dependent effects of chronic Niagen supplementation. 132
healthy overweight adults completed the randomized, double-blind,
placebo-controlled, parallel arm trial. The results show how
supplementation with three different daily doses of Niagen (100 mg,
300 mg, 1000 mg) initially increase and then sustain elevated blood
NAD levels over the course of an 8-week period.
The results of this study directly support the NAD-boosting
efficacy of Tru Niagen, which recommends a daily serving size of
300 mg in the United States. On average, study participants
consuming 300 mg/day experienced a statistically significant 51%
increase in whole blood NAD+ within two weeks. This increase was
maintained throughout the remainder of the eight-week study.
The study also joins previous chronic supplementation studies to
support the safety of chronic Niagen supplementation. All doses
tested were well-tolerated with no attributable adverse events
reported. By the end of the eight-week trial, no changes in LDL
cholesterol levels or blood levels of homocysteine were observed.
These results further differentiate Niagen from other NAD-boosting
supplements and support the establishment of a unique upper limit
for Niagen versus other B3 vitamins.
“This is a timely publication in the history of Niagen as it
clearly shows safe, dose-dependent and time-dependent increases in
blood NAD in human populations,” said Charles Brenner, PhD, Roy J.
Carver Chair & Head of Biochemistry at the University of Iowa
& ChromaDex Chief Scientific Advisor. “With so much global
interest in NAD-boosting supplementation strategies, our approach
to human translation has been to put safety first. These data will
be used to design the next generation of trials to promote wellness
as well as to test the activity of Niagen against diseases and
conditions of metabolic stress.”
“This clinical study builds upon a body of research
demonstrating the safe and sustained benefits of Niagen
supplementation, and importantly identifies optimal dosing to
achieve increased NAD levels over time,” said Matthew Roberts, PhD,
Chief Scientific Officer, ChromaDex.
To date, ChromaDex has invested millions of dollars in safety
and human clinical trials on its patent-protected NR (commercially
known as Niagen) and has entered research agreements with more than
160 leading institutions for research, including Dartmouth, the
National Institutes of Health, University of Iowa, and the Scripps
Research Institute.
NIAGEN® is the only commercially available nicotinamide riboside
which has twice been successfully reviewed under FDA's new dietary
ingredient (NDI) notification program and has also been
successfully notified to the FDA as generally recognized as safe
(GRAS).
For additional information on the science supporting Niagen
visit www.chromadex.com.
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended, including
statements related to the results of the Niagen study, its
validation of safety and efficacy, and is significance for future
Niagen studies. Statements that are not a description of historical
facts constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a portion of
the grant funding as a collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships949-648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor
Relations949-344-3782briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024